Policy & Regulation
FDA grants Priority Review to Genentech's Enspryng for MOGAD
10 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), said on Thursday that the US Food and Drug Administration (FDA) has granted Priority Rev...
BioMarin announces positive Phase 3 VOXZOGO (vosoritide) study results in hypochondroplasia published in NEJM Evidence
10 September 2026 - Biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) announced on Wednesday that new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO (vosoritide) in children...
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
10 September 2026 - Seismic Pharmaceuticals, a biotechnology company focused on advancing novel treatments for heart failure, announced on Wednesday the enrolment of the first patient in its global Ph...
BioEdge Research Labs advances transparency in research compound documentation
10 September 2026 - BioEdge Research Labs, a US-based supplier of research peptides and reference materials, on Wednesday announced an initiative to advance transparency in how its research materials ...
Insilico Medicine doses first patient in Phase III trial of rentosertib
10 September 2026 - Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Wednesday that it has dosed the first patient with rentosertib (known as ISM001-055 / INS018_055) in...
BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib
9 September 2026 - US biopharmaceutical company BridgeBio Pharma, Inc. (NASDAQ: BBIO), which develops medicines for genetic conditions, on Wednesday announced the release of new exploratory analyses f...